Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 16/20 | 0.77 |
| ▸ | NOTCH3 | Q9UM47 | 15/20 | 0.77 |
| ▸ | NOTCH2 | Q04721 | 1/20 | 0.77 |
| ▸ | NOTCH4 | Q99466 | 1/20 | 0.77 |
| ▸ | CCKBR | P32239 | 2/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.61 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.61 |
| ▸ | RBPJ | Q06330 | 1/20 | 0.61 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.61 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.61 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12690228 | 0.96 | NOTCH1 (0.73) | NOTCH1NOTCH3NOTCH2NOTCH4CCKBR | |
| SCHEMBL12690227 | 0.96 | NOTCH1 (0.77) | NOTCH1NOTCH3NOTCH2NOTCH4CCKBR | |
| SCHEMBL12542696 | 0.94 | NOTCH1 (0.78) | NOTCH1NOTCH3NOTCH2NOTCH4CCKBR | |
| SCHEMBL12543029 | 0.94 | NOTCH1 (0.78) | NOTCH1NOTCH3NOTCH2NOTCH4CCKBR | |
| Osugacestat SCHEMBL29412689 | 0.92 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4CCKBR | |
| Osugacestat SCHEMBL21577519 | 0.92 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4CCKBR | |
| Osugacestat SCHEMBL12543867 | 0.92 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4CCKBR | |
| Osugacestat SCHEMBL12543868 | 0.92 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4CCKBR | |
| Osugacestat SCHEMBL17420836 | 0.92 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4CCKBR | |
| Osugacestat SCHEMBL15622455 | 0.92 | NOTCH1 (0.84) | NOTCH1NOTCH3NOTCH2NOTCH4CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381196-A1 | COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING ADENOID CYSTIC CARCINOMA | AYALA PHARMACEUTICALS INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20160060232-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-03 | — | — | US | disclosed |
| US-9273075-B2 | Prodrugs of 1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150284342-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150232491-A1 | PRODRUGS OF 1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-20 | — | — | US | disclosed |
| US-20140357605-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-04 | — | — | US | disclosed |
| US-8822454-B2 | Bisfluoroalkyl-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8629136-B2 | Bisfluoroalkyl-1,4-benzodiazepinone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-14 | — | — | US | disclosed |
| US-20120245151-A1 | BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381196-A1 | COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING ADENOID CYSTIC CARCINOMA | AKR1C3, AKR1D1, CYP2C19 | NOTCH1 3781/4885NOTCH3 4248/4885NOTCH2 4683/4885 |
| US-20150232491-A1 | PRODRUGS OF 1,4-BENZODIAZEPINONE COMPOUNDS | CNR1, RXFP1, CNR2 | NOTCH1 158/4885NOTCH3 386/4885NOTCH2 428/4885 |
| US-20140357605-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | CNR1, CNR2, NR1I3 | NOTCH1 12/4885NOTCH3 6/4885NOTCH2 57/4885 |
| US-20120245151-A1 | BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS | CNR1, CYP2F1, RORC | NOTCH1 29/4885NOTCH3 20/4885NOTCH2 111/4885 |
| US-20160060232-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | CNR1, CNR2, NR1I3 | NOTCH1 12/4885NOTCH3 6/4885NOTCH2 57/4885 |
| US-20150284342-A1 | BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS | CNR1, CNR2, NR1I3 | NOTCH1 12/4885NOTCH3 6/4885NOTCH2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.